Jane Wainwright

Jane is an experienced life science patent attorney with considerable experience of coordinating patent strategies across the world, including both patent prosecution and third-party issues. She has also been involved in a number of due diligence projects relating to company and IP acquisitions, for both acquirer and acquiree.

With a focus on providing commercially relevant advice for her clients, Jane works with a number of organisations including universities, SMEs and multinational corporations.

She specialises in the field of biotechnology and deals with subjects including recombinant technology, antibody therapies, drug screening assays and gene therapy technologies. She also handles patent applications in a number of biotechnology and chemistry cross-over areas, in particular, combined chemical-biotechnology assays for biological sample assessment and the biological production of modified chemical compounds. 

Jane regularly advises her clients on all aspects of filing and prosecution strategy, as well as third-party issues such as oppositions, third party observations and due diligence investigations. In particular, she has considerable experience planning worldwide patenting strategies and co-ordinating their implementation before numerous patent offices, as well as directly representing clients at the European Patent Office (EPO).  

Jane has spoken at international conferences on various points of European law and practice and has authored a number of opinions and educational pieces on issues arising in UK and European law.

She joined Potter Clarkson in 2001 and became a partner in 2011.